Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children’s Oncology Group

BACKGROUND: Juvenile myelomonocytic leukemia (JMML) is not durably responsive to chemotherapy, and approximately 50% of patients relapse after hematopoietic stem cell transplant (HSCT). Here we report the activity and acute toxicity of the farnesyl transferase inhibitor tipifarnib, the response rate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Stieglitz, Elliot, Ward, Ashley F., Gerbing, Robert B., Alonzo, Todd A., Arceci, Robert J., Liu, Y. Lucy, Emanuel, Peter D., Widemann, Brigitte C., Cheng, Jennifer W., Jayaprakash, Nalini, Balis, Frank M., Castleberry, Robert P., Bunin, Nancy J., Loh, Mignon L., Cooper, Todd M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4339233/
https://ncbi.nlm.nih.gov/pubmed/25704135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25342
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados